3 results
Approved WMOCompleted
To investigate the bleeding pattern and cycle control parameters of the transdermal contraceptive patch (material no. 80876395, FC Patch Low containing 0.55 mg EE and 2.1 mg GSD) in comparison to the EVRA patch (containing 0.6 mg EE and 6 mg NGMN).
Approved WMOCompleted
This study will be performed to evaluate the safety of the ACE stapler for the treatment of obesity. The secondary objective is to evaluate effectiveness of the ACE stapler for the treatment of obesity.
Approved WMOCompleted
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.